Brief: Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 As A Treatment For Patients With Major Depressive Disorder Characterized By An Electroencephalogram Biomarker
19/02/2025 15:08
Feb 19 (Reuters) - Alto Neuroscience Inc ANRO.N :
* ALTO NEUROSCIENCE ANNOUNCES U.S. PATENT GRANTED COVERING
ALTO-300 AS A TREATMENT FOR PATIENTS WITH MAJOR DEPRESSIVE
DISORDER CHARACTERIZED BY AN ELECTROENCEPHALOGRAM BIOMARKER
Source text: ID:nBw56gCPna
Further company coverage: ANRO.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alto Neuroscience
See all newsBrief: Alto Neuroscience Promotes Nick Smith To President And Chief Financial Officer
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Brief: Alto Neuroscience - Proposed Resale Of Up To 6 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
Brief: Alto Neuroscience Reports Topline Data From Phase 2 Proof-Of-Concept Study Of Alto-101 And Highlights Pipeline Advancements